Covid-19 manufacturing roundup: Catalent gets the FDA's go-ahead on J&J shot; AstraZeneca taps a new contractor
The FDA has authorized an Indiana CDMO to produce and ship millions of doses of J&J’s Covid-19 vaccine.
Catalent Pharma tweeted the news and an accompanying video from its Bloomington facility last week. The manufacturer received a EUA, which puts J&J a step closer toward meeting its goal of providing the US with 100 million doses by the end of June.
Today, Catalent is proud to share that our Bloomington, Indiana site’s recently completed expansion received Emergency Use Authorization from the FDA to produce and ship millions of doses of Johnson & Johnson’s COVID-19 vaccine. Learn more: https://t.co/jFg5OoWkyO @JNJNews pic.twitter.com/rDhSl8Uois
— Catalent Pharma (@CatalentPharma) March 23, 2021
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
